When the transgenic AquAdvantage salmon was first developed in 1989, the goal was simple: engineer a fast-growing fish that required fewer resources and provided an equivalent amount of salmon compared to its non-GMO counterpart. 30 years later, AquAdvantage salmon is expected to boost the sustainability of fish farming and provide consumers with an affordable, high-quality source of protein as it enters the market. Biotech firm AquaBounty anticipates its GMO salmon will be in US grocery stores in late 2020.
As the first (and so far only) GMO animal to be approved for human consumption, AquAdvantage salmon endured 15 years of regulatory review as officials in the US and Canada thoroughly evaluated its potential nutritional and environmental impacts. On this episode of the Talking Biotech podcast, plant geneticist Kevin Folta speaks with Sylvia Wulf, CEO and President of AquaBounty Technologies. They discuss the genesis of GMO salmon, how the fish will be kept out of the oceans, and why politics stalled the introduction of AquAdvantage for so long.
The Talking Biotech podcast, produced by Kevin Folta, is available for listening or subscription: